Bravecto 500mg Spot-on for Large Cats 6.25 - 12.5kg (single pipette)
|Manufacturer||MSD Animal Health|
|Prescription Type||POM-V (Written prescription required)|
Bravecto Spot-On is an antiparasitic designed to be given for the management of flea or tick infestations in cats. A single dose can provide 12 weeks of protection from fleas and most types of ticks. Suitable for small cats (1.2 - 2.8kg).
Indications for use
For the treatment of tick and flea infestations in cats.
This veterinary medicinal product is a systemic insecticide and acaricide that provides:
- immediate and persistent flea (Ctenocephalides felis) killing activity for 12 weeks,
- immediate and persistent tick killing activity for 12 weeks for Ixodes ricinus.
- treatment of infestations with ear mites (Otodectes cynotis).
Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance. The onset of effect is within 8 hours of attachment for fleas (C. felis) and 12 hours of attachment for ticks (I. ricinus).
The product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).
This is a Prescription Only Medicine (POM-V)
Bravecto Spot On is only available with a prescription from your veterinary surgeon.
To check the most up to date information about this product, please read its Summary of Product Characteristics (SPC) below:
Fluralaner is an acaricide and insecticide. It is efficacious against ticks (Ixodes spp.), fleas (Ctenocephalides spp.) and ear mites (Otodectes cynotis) on the cat. The onset of efficacy is within 12 hours for fleas (C.felis) and within 48 hours for ticks (I.ricinus).
It has a high potency against ticks and fleas by exposure via feeding, i.e. it is systemically active on target parasites.Fluralaner is a potent inhibitor of parts of the arthropod nervous system by acting antagonistically on ligand-gated chloride channels (GABA-receptor and glutamate-receptor). In molecular on-target studies on insect GABA receptors of flea and fly, fluralaner is not affected by dieldrin resistance.
In in vitro bio-assays, fluralaner is not affected by proven field resistances against amidines (tick), organophosphates (tick, mite), cyclodienes (tick, flea, fly), macrocyclic lactones (sea lice), phenylpyrazoles (tick, flea), benzophenyl ureas (tick), pyrethroids (tick, mite) and carbamates (mite).
The product contributes towards the control of the environmental flea populations in areas to which treated cats have access.
Newly emerged fleas on a cat are killed before viable eggs are produced. An in vitro study also demonstrated that very low concentrations of fluralaner stop the production of viable eggs by fleas.The flea life cycle is broken due to the rapid onset of action and long lasting efficacy against adult fleas on the animal and the absence of viable egg production.
Bravecto is a prescription product and must be applied according to the instructions by your veterinary surgeon.
Please read the product leaflet thoroughly before applying to your pet.
Marketing Authorisation Holder
Intervet International BV, The Netherlands
Marketing Authorisation Number
- Do not use in case of hypersensitivity to the active substance or to any of the excipients.
Special warnings for each target species
- Parasites need to start feeding on the host to become exposed to fluralaner; therefore the risk of the transmission of parasite borne diseases cannot be excluded.
Special precautions for use in animals
Care should be taken to avoid contact with the eyes of the animal.
Do not use directly on skin lesions.
In the absence of available data, this veterinary medicinal product should not be used on kitten less than 9 weeks old and /or cats weighing less than 1.2 kg.
The product should not be administered at intervals shorter than 8 weeks as the safety at shorter intervals has not been tested.
This product is for topical use and should not be administered orally.
Do not allow recently treated animals to groom each other.
Contact with the product should be avoided and disposable protective gloves obtained with this product at the point of sale must be worn when handling the product for the following reasons:• Hypersensitivity reactions have been reported in a small number of people, which can potentially be serious.• Persons with a hypersensitivity to fluralaner or to any of the excipients should avoid any exposure to the product.• The product binds to skin and may also bind to surfaces after spillage of the product. Skin rashes, tingling or numbness have been reported in a small number of individuals after skin contact.
If skin contact does occur, wash the affected area immediately with soap and water. In some cases, soap and water are not sufficient to remove the product spilled on the fingers.
Contact with the product may also occur when handling the treated animal.
Make sure that your animal’s application site is no longer noticeable before resuming contact with the site of application. This includes cuddling the animal and sharing a bed with the animal. It takes up to 48 hours for the application site to become dry but it will be noticeable for longer.
If skin reactions occur, consult a physician and show them the product packaging.
People with a sensitive skin or known allergy in general e.g. to other veterinary medicinal products of this type should handle the veterinary medicinal product as well as treated animals with caution.
This product can cause eye irritation. In case of contact with the eyes, immediately rinse thoroughly with water.
This product is harmful after ingestion. Keep the product in the original packaging until use, in order to prevent children from getting direct access to the product. A used pipette should immediately be disposed of. In case of accidental ingestion, seek medical advice and show the package leaflet or the label to the physician.
The product is highly flammable. Keep away from heat, sparks, open flame or other sources of ignition.In case of spillage onto, for example table or floor surfaces, remove excess product using paper tissue and clean the area with detergent.
Mild and transient skin reactions at the application site, such as erythema and pruritus or alopecia were commonly observed in clinical trials (2.2% of treated cats).
The following other signs shorterly after administration were observed:• Apathy/tremors/anorexia (0.9% of treated cats) or vomiting/hypersalivation (0.4% of treated cats).
- The frequency of adverse reactions is defined using the following convention:
• Very common (more than 1 in 10 animals displaying adverse reaction(s) during the course of one treatment)
• Common (more than 1 but less than 10 animals in 100 animals)
• Uncommon (more than 1 but less than 10 animals in 1,000 animals)
• Rare (more than 1 but less than 10 animals in 10,000 animals)
• Very rare (less than 1 animal in 10,000 animals, including isolated reports).
Use during pregnancy, lactation or lay
The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Use only accordingly to the benefit/risk assessment by the responsible veterinarian.
- None known.
Fluralaner is highly bound to plasma proteins and might compete with other highly bound drugs such as non-steroidal anti-inflammatory drugs (NSAIDs) and the cumarin derivative warfarin. Incubation of fluralaner in the presence of carprofen or warfarin in dog plasma at maximum expected plasma concentrations did not reduce the protein binding of fluralaner, carprofen or warfarin.
During clinical field testing, no interactions between Bravecto chewable tablets for dogs and routinely used veterinary medicinal products were observed.
Show products for :